Ilyang Pharmaceutical Co Ltd (007575) — Cash Flow Reinvestment Rate
Ilyang Pharmaceutical Co Ltd (007575) has a Cash Flow Reinvestment Rate of 3.94x as of June 2025, reinvesting ₩8.90 Billion (capex ₩3.32 Billion plus investments ₩-5.59 Billion) from operating cash flow of ₩2.26 Billion. See 007575 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Ilyang Pharmaceutical Co Ltd Cash Flow Reinvestment Rate (2014–2024)
Historical reinvestment intensity for Ilyang Pharmaceutical Co Ltd across 11 annual periods. For the full cash flow conversion analysis, see Ilyang Pharmaceutical Co Ltd cash conversion from operations.
Annual Cash Flow Reinvestment Rate for Ilyang Pharmaceutical Co Ltd (2014–2024)
Year-by-year capital reinvestment analysis for Ilyang Pharmaceutical Co Ltd. See 007575 free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 13.86x | ₩77.80 Billion | ₩5.61 Billion | ₩40.62 Billion | ▲ +1004.0% |
| 2023 | 1.26x | ₩18.35 Billion | ₩14.62 Billion | ₩6.83 Billion | ▲ +16.7% |
| 2022 | 1.08x | ₩32.20 Billion | ₩29.94 Billion | ₩4.08 Billion | ▲ +434.9% |
| 2021 | 0.20x | ₩13.48 Billion | ₩67.02 Billion | ₩12.91 Billion | ▲ +12.3% |
| 2020 | 0.18x | ₩10.29 Billion | ₩57.48 Billion | ₩10.17 Billion | ▼ -25.2% |
| 2019 | 0.24x | ₩8.67 Billion | ₩36.19 Billion | ₩2.17 Billion | ▲ +104.4% |
| 2018 | 0.12x | ₩2.59 Billion | ₩22.12 Billion | ₩1.55 Billion | ▼ -53.7% |
| 2017 | 0.25x | ₩7.60 Billion | ₩30.03 Billion | ₩3.78 Billion | ▼ -67.4% |
| 2016 | 0.78x | ₩20.98 Billion | ₩26.98 Billion | ₩10.31 Billion | ▲ +87.2% |
| 2015 | 0.42x | ₩16.72 Billion | ₩40.27 Billion | ₩16.07 Billion | ▼ -44.4% |
| 2014 | 0.75x | ₩13.92 Billion | ₩18.63 Billion | ₩13.89 Billion | — |